SML3101

MLi-2

≥98% (HPLC), selective leucine-rich repeat kinase 2 (LRRK2) inhibitor, powder

• Synonym(e): cis-2,6-Dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine, rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidinyl]-5-[(1-methylcyclopropyl)oxy]-1H-iIndazole
• Empirische Formel (Hill-System): C₂₁H₂₅N₅O₂
• CAS-Nummer: 1627091-47-7
• Molekulargewicht: 379.46
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD30536362
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: MLi-2, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (warmed)
• storage temp.: 2-8°C
• SMILES string: C[C@]([H])(O[C@@]([H])(C1)C)CN1C2=CC(C3=NNC(C3=C4)=CC=C4OC5(C)CC5)=NC=N2
• InChI key: ATUUNJCZCOMUKD-OKILXGFUSA-N

Beschreibung

Biochem/physiol Actions

CNS active, highly potent and selective LRRK2 inhibitor

MLi-2 is an orally available, CNS active, highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor. MLi-2 potently inhibits central and peripheral LRRK2 in mice.

Other Notes

2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• Was ist los?: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable